OncoResponse

18 articles with OncoResponse

• OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  OncoResponse announced that Clifford Stocks, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11 a.m. PST.

• OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022

  11/11/2022

  OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Responders, today announced preclinical data on immuno-oncology candidates OR2805 and OR502 presented at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting.

• 

  OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective

  5/10/2022

  OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response. 

• OncoResponse Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress and World Antibody Congress 2022

  3/2/2022

  OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced that the company will present at the upcoming Festival of Biologics World Immunotherapy Congress and World Antibody Congress taking place March 9 - 11, 2022 in San Diego, California.

• 

  Beyond the Business Pitch - Plan, Build Relationships and Deliver Succinctly

  1/5/2022

  This year’s virtual J.P. Morgan Week is spurring companies to expand meeting slots throughout the month and conduct more relaxed, productive encounters.

• OncoResponse to Present at Upcoming Investor Conferences

  11/22/2021

  OncoResponse today announced that Clifford Stocks, Chief Executive Officer, will participate in two upcoming investor conferences.

• OncoResponse Appoints Renowned Immunologists Drs. Miriam Merad and David G. DeNardo to Scientific Advisory Board

  11/9/2021

  OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, announced the appointments of Miriam Merad, MD, PhD, and David G. DeNardo, PhD, to the company's scientific advisory board.

• OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer

  11/2/2021

  OncoResponse today announced initiation of a Phase 1/2 study of OR2805 in patients with advanced cancer. OR2805 is a fully human monoclonal antibody identified from an elite cancer responder

• OncoResponse Appoints Sean McCarthy to Board of Directors

  7/7/2021

  OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to immunosuppressive myeloid targets for cancer immunotherapy, announced the appointment of Sean A. McCarthy, D. Phil., as an Independent Director to its Board of Directors.

• OncoResponse Appoints Chris Russell as Chief Financial Officer

  5/11/2021

  OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to immunosuppressive myeloid targets for cancer immunotherapy, announced the appointment of Chris Russell as Chief Financial Officer.

• 

  Money on the Move: March 31 – April 6

  4/7/2021

  April springs up with showers of cash for these life sciences companies.

• OncoResponse Raises $40.6 Million Series C Financing

  3/31/2021

  - New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies -  Adds Magnetar Group, Yonjin Ventures and Bering Capital to the syndicate

• OncoResponse Raises $40 Million in Series B Financing

  9/11/2018

  Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers

• OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D

  1/2/2018

  OncoResponse today announced it has expanded its scientific leadership through the additions of Anil Singhal, Ph.D., and Kamal D. Puri, Ph.D., to the management team.

• OncoResponse Adds Anti-EMP2 Antibody to Oncology Pipeline Through Acquisition of Paganini Biopharma

  11/7/2017

  OncoResponse today announced that it has closed the acquisition of Paganini Biopharma, acquiring all of its assets including an anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201.

• OncoResponse Announces Final Closing Of $22.5M Series A Financing Round

  3/9/2017

• OncoResponse Secures $7 Million In Supplemental Series A Funding

  10/10/2016

• Helsinn Investment Fund To Invest $3.5 Million In OncoResponse

  10/10/2016